Filing Impact
Filing Sentiment
Form Type
4
Outlook Therapeutics Inc
Jul 31, 2025
[SCHEDULE 13G] Outlook Therapeutics, Inc. SEC Filing
119.93M
28.25M
36.39%
20.53%
5.48%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
ISELIN